• Lucid Diagnostics Inc LUCD.OQ reported a quarterly adjusted loss of 25 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -34 cents. The mean expectation of six analysts for the quarter was for a loss of 22 cents per share. Wall Street expected results to range from -23 cents to -20 cents per share.

• Revenue rose 49.7% to $1.17 million from a year ago; analysts expected $1.14 million.

• Lucid Diagnostics Inc's reported EPS for the quarter was a loss of 25 cents​.

• The company reported a quarterly loss of $12.37 million.

• Lucid Diagnostics Inc shares had risen by 22.7% this quarter and lost 29.1% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 2.7% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is also "buy"

Wall Street's median 12-month price target for Lucid Diagnostics Inc is $3.00

This summary was machine generated from LSEG data November 13 at 03:27 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)